Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Hepatitis c | D006526 | — | B19.2 | 6 | 2 | — | — | 1 | 8 |
Hepatitis | D006505 | HP_0012115 | K75.9 | 6 | 2 | — | — | 1 | 8 |
Chronic hepatitis c | D019698 | EFO_0004220 | B18.2 | 5 | 2 | — | — | — | 6 |
Hepatitis a | D006506 | EFO_0007305 | B15 | 1 | 2 | — | — | — | 2 |
Chronic hepatitis | D006521 | — | K73.9 | — | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Chronic hepatitis b | D019694 | EFO_0004239 | B18.1 | 2 | — | — | — | — | 2 |
Drug common name | SAMATASVIR |
INN | samatasvir |
Description | Samatasvir (IDX-719) is an experimental drug for the treatment of hepatitis C. It was originally developed by Idenix, and development has been continued by Merck & Co. following their acquisition of Idenix. Samatasvir has shown good results in Phase II trials.
|
Classification | Small molecule |
Drug class | antivirals: nonstructural protein 5A (NS5A) inhibitors |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | COC(=O)N[C@H](C(=O)N1CCC[C@H]1c1nc2cc(-c3csc4c(-c5ccc(-c6c[nH]c([C@@H]7CCCN7C(=O)[C@H](NC(=O)OC)c7ccccc7)n6)cc5)csc34)ccc2[nH]1)C(C)C |
PDB | — |
CAS-ID | — |
RxCUI | — |
ChEMBL ID | CHEMBL3039519 |
ChEBI ID | — |
PubChem CID | 53302707 |
DrugBank | — |
UNII ID | 21P699C5FC (ChemIDplus, GSRS) |